Clinical Trial Update: A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/IIa study of EF-009 for pancreatic cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• EF-009

Snippet

Sponsor: Everfront Biotech Co., Ltd. | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING